Antibiotics
Antibiotics are commonly prescribed to treat eye infections caused by bacteria. Some common antibiotics used for ophthalmic purposes include:
Tetracyclines such as doxycycline and minocycline work against a wide variety of bacteria including those that cause conjunctivitis (pink eye). They are usually prescribed as eye drops or ointments. These antibiotics are well-tolerated with minimal side effects.
Fluoroquinolones like ciprofloxacin and ofloxacin are broad-spectrum antibiotics effective against both gram-positive and gram-negative bacteria. They are prescribed for various bacterial eye infections like conjunctivitis, keratitis, and blepharitis. Topical fluoroquinolones are well-absorbed in the eye and reduce infection quickly with minimal adverse effects.
Aminoglycosides including gentamicin, tobramycin and amikacin help treat bacterial infections resistant to other classes of antibiotics. They are commonly used alongside another antibiotic for enhanced treatment of severe infections. Local side effects are rare with aminoglycoside eye drops but they should be used with caution in patients with renal impairment.
Anti-Inflammatory Drugs
Due to their anti-inflammatory properties, corticosteroids are often prescribed to reduce inflammation, swelling and discomfort associated with various eye conditions.
Corticosteroids like prednisolone, fluorometholone and loteprednol etabonate quickly relieve symptoms of redness, itching and irritation caused by conjunctivitis, uveitis, keratitis and post-surgery recovery. Topical corticosteroids are generally well-tolerated but may cause side effects with long-term use such as increased eye pressure and cataract formation.
Non-steroidal anti-inflammatory drugs (NSAIDs) including ketorolac, bromfenac and diclofenac work by blocking prostaglandin production. They are effective for symptomatic relief in conditions with ocular inflammation and pain like conjunctivitis, anterior uveitis, macular edema and post-surgical discomfort. NSAIDs typically have a better safety profile than corticosteroids with lower risks of glaucoma and cataracts.
Anti-Glaucoma Drugs
Glaucoma is a group of diseases characterized by increased pressure within the eye or optic nerve damage which can lead to vision loss if left untreated. Various medications are used to lower eye pressure in glaucoma:
Prostaglandin analogs like latanoprost, travoprost and bimatoprost work by increasing fluid outflow from the eye. Ophthalmic Drugs They are considered first-line treatment for glaucoma due to their high effectiveness and once-daily dosing with minimal side effects.
Beta blockers including timolol, levobunolol and betaxolol reduce fluid production inside the eye. They are well-tolerated but may cause breathlessness, bradycardia or hypoglycemia in susceptible individuals.
Carbonic anhydrase inhibitors such as dorzolamide and brinzolamide decrease fluid secretion. Topical administration results in few systemic side effects.
Alpha-adrenergic agonists like brimonidine protect the optic nerve by decreasing aqueous humor production. Common side effects include allergic conjunctivitis and dry mouth.
Combined medications containing both a beta blocker and carbonic anhydrase inhibitor in one drop offer enhanced IOP reduction with convenience of once-daily dosing.
Other Ophthalmic Drugs
In addition to antibiotics, anti-inflammatories and glaucoma medications, ophthalmologists may prescribe other types of eye drops or ointments to treat various ocular conditions:
Antihistamines - Oral as well as topical formulations of olopatadine, ketotifen and epinastine provide relief from allergic conjunctivitis symptoms.
Miotic agents - Pilocarpine is a parasympathomimetic miotic used to constrict the pupil and treat acute angle closure glaucoma by pulling the iris away from the trabecular meshwork.
Mydriatic agents - Atropine, homatropine and tropicamide are anticholinergic medications that dilate the pupil during eye exams by blocking the muscles that constrict the pupil.
Cycloplegic agents - Cyclopentolate and tropicamide are anticholinergic eyedrops that induce paralysis of the ciliary muscle resulting in dilation of the pupil and relaxation of accommodation during examination of the eye.
Artificial tears - Lubricating drops like hypromellose, carbomer, polyethylene glycol and glycerin are used to temporarily relieve dry, irritated or gritty eyes. Preservative-free varieties are recommended for frequent use.
Get more insights on Ophthalmic Drugs
Transparency Market Research (TMR) has published a new report titled, ‘Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the global Ophthalmic Drugs Market was valued at US$ 26,018.3 Mn in 2018 and is projected to expand at a CAGR of 4.1% from 2019 to 2027.Read Report Overview - https://www.transparencymarketresearch.com/ophthalmic-drugs-market.htmlOverviewOphthalmic Drugs are the anti-infectives drugs that contained in a product formulated especially to be instilled or applied in the eye or eyes.
Ophthalmic anti-infectives include eye drops, gels or ointments.
Highly structured health care industry and introduction of the Affordable Care Act in the U.S. are expected to drive the market in North America.Asia Pacific is likely to be a highly lucrative market for retinal disorders and it is expected to expand at a high CAGR during the forecast periodRequest Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1769Increasing incidence rates of eye related disorders to Drive MarketThere is an alarming rise in incidence of eye related diseases, especially in the developed countries, which is anticipated to drive the growth of the ophthalmic drugs market during 2017-2025According to the Prevent Blindness report, the number of people in the U.S., suffering from cataract is expected to increase from4 Mnin 2010, to 30.5 Mn by 2020, and people suffering from diabetic retinopathy in U.S. are projected to increase from 7.7 Mn in 2010 to 9.2 Mn in 2020The patients for open angle glaucoma and AMD in U.S., were 7 Mn and 2.1 Mn, respectively, which are projected to increase to3.3 Mn and 2.5 Mn, respectively, till 2020The increasing patient pool in developing countries as well as developed regions is estimated to propel healthcare spending for eye treatments in each region and drive the growth of the ophthalmic drugs market.Advanced retinal treatment approvals for unmet needs in eye disorders to drive the marketEye diseases such as chronic or recurrent uveitis, optic nerve, neurodegeneration retinitis pigmentosa, retinoblastoma, etc., lack an effective treatment option, and thus are categorized as unmet medical needs within the ophthalmologic diseases spaceSeveral new entrants are dedicated to provide specialized treatment methods for eye diseases:On May 18 2017,Spark Therapeutics, Inc. submitted the first and only Biological License Application to the U.S. FDA for the treatment of Leber’s congenital amaurosis by gene therapyOn March 25 2015, Regeneron Pharmaceuticals Inc., announced the approval of Eylea, the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of diabetic macular edemaSevere inflammatory eye diseases, such as uveitis, lacked a solid treatment option earlier to the FDA approval of Humira for the indication of non-infectious intermediate, posterior, and panuveitis in adult patientsIn June 2016,the U.S. FDA approved the first and only biologic approved drug, Humira, for the treatment of uveitisSuch approvals for advanced treatment options for the treatment of unmet medical needs in the field of eye disorders are projected to boost the expansion of the global ophthalmic drugs marketRequest COVID Analysis on Ophthalmic Drugs Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=1769Dry Eye Segment to Dominate MarketBased on Disease Indication, the global Ophthalmic Drugs Market has been divided into Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, Others.
The Retinal Disorders segment has been bifurcated into Wet AMD, Dry AMD, Diabetic Retinopathy, Others.
The market is witnessing significant transformations due to changing Medicare policies in the U.S., pricing of branded specialty drugs, and the rising patient pool.The increasing patient number along with rising health initiatives for treatment awareness are projected to drive the demand for ophthalmic drugs in this region.The Ophthalmic Drugs Market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027.
The global ophthalmic drugs market is witnessing rapid increase over the past few years, mainly due to the rising prevalence of eye-related diseases & disorders.
Recent advances in medical technologies such as AMPPLIFY technology that demonstrates higher delivery of a drug into ocular tissues are escalating the market on the global platform.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5753An eminent research firm Market Research Future (MRFR) states that the global ophthalmic drugs market size had reached USD 29.46 BN in 2018, and the market valuation would further appreciate at around 5.1% CAGR during the forecast period (2019 to 2025).
Substantial R investments into drug discoveries are another major tailwind pushing the market growth excellently, bringing about novel medicines to treat various ophthalmic diseases.
Furthermore, recent development & commercialization of several drugs boost the market growth.Global Ophthalmic Drugs Market – SegmentsThe report has been segmented into five major dynamics.By Dosage Form : Eye Drops, Ointments, Solutions, Gels, Capsules & Tablets, and others.By Product Type : Prescription Drug and OTC Drug.By Drug Class : Antibiotics, Anti-Inflammatory, Anti-Glaucoma, and others.By Indication : Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, and others.By Regions : Europe, Americas, Asia Pacific, Middle East & Africa, and Rest-of-the-World.Global Ophthalmic Drugs Market – Regional AnalysisNorth America leads the global ophthalmic drugs heading with the presence of the many major players and a large patient population suffering from eye diseases.
Moreover, the availability of well-developed technology and high healthcare expenditures, alongside the rising prevalence of eye diseases in the region, drives the market growth significantly.Also, the growing demand for eye care led by the increasing numbers of patients suffering from chronic diseases such as diabetes, neurovascular, and different eye disorders impacts market growth positively.
Additionally, augmenting demand for the minimally invasive & technologically advanced treatments, alongside the governmental support for R funding are expected to drive the regional market growth, commutatively.Europe's ophthalmic drugs market is proliferating rapidly.
The global ophthalmic drugs market size is expected to reach USD 45.8 billion by 2027, registering a CAGR of 5.0%, according to a new report published by Radiant Insights, Inc. Advancements in drug delivery systems are anticipated to drive the overall growth.
In December 2017, Spark Therapeutics received Food and Drug Administration (FDA) approval for the first gene therapy drug in the ophthalmic market-Luxturna (voretigene neparvovec-rzyl).
Download Free Sample Report @ https://www.radiantinsights.com/research/ophthalmic--drugs-market/request-sample Increasing number of strategic mergers, acquisitions, and collaborations make the market for ophthalmic drugs a highly competitive space.
Premium services and high-volume ancillary value-added businesses deliver supplementary benefits to customers and attract investments in the market.
For instance, in July 2019, Bausch & Lomb Incorporated announced launch of Ocuvite, an eye vitamin supplement to strengthen the macula for the U.S. market.
Due to increasing awareness of ophthalmic disorders and surge in the demand of these products, ophthalmic drug manufacturers are expanding their presence in the emerging economies by supporting various awareness campaigns in different regions.
